Table 1.
Gleason sum scores, therapy characteristics and staining intensities of the antibodies in the salvage prostatectomy specimens.
| Patient No. | Radiotherapy (Dose in Gy) | Hormonal Status Prior to Salvage Prostatectomy | Interval between Radiotherapy and Salvage Prostatectomy (Months) | Stage | Gleason | PSMA | EpCAM | VEGF | GRPR |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EBRT (Dose unknown) | LHRH + AA | 51 | pT3b | 7 | ++ | + | ++ | +++ |
| 2 | Brachytherapy (HDR) | None | 45 | pT2c | 8 | + | ++ | ++ | +++ |
| 3 | EBRT (70) | LHRH + AA | 58 | pT3b | 8 | + | − | + | +++ |
| 4 | EBRT (70) | None | 24 | pT3a | 7 | + | + | − | ++ |
| 5 | EBRT (Dose unknown) | None | 80 | pT2c | 7 | ++ | + | − | + |
| 6 | Brachytherapy (LDR) | None | 47 | pT2c | cnd | + | + | − | +++ |
| 7 | EBRT (70) | LHRH + AA | 120 | pT3a | 7 | +++ | − | + | + |
| 8 | EBRT (66) | None | 31 | pT3b | 8 | + | − | + | + |
| 9 | EBRT (66) | None | 78 | pT4 | 7 | +++ | +++ | + | +++ |
| 10 | EBRT (66) | None | 48 | pT3b | 8 | +++ | ++ | ++ | +++ |
| 11 | EBRT (Dose unknown) | Unknown | 63 | pT3b | 7 | +++ | +++ | +++ | ++ |
| 12 | Brachytherapy (LDR) | None | 41 | pT4 | 7 | +++ | +++ | + | ++ |
| 13 | EBRT (70) | None | 49 | pT3a | 8 | + | ++ | ++ | ++ |
| 14 | EBRT (68) | LHRH | 58 | pT3a | 6 | +++ | +++ | ++ | +++ |
| 15 | Brachytherapy (LDR) | AA | 88 | pT3b | 8 | +++ | ++ | ++ | +++ |
| 16 | EBRT (68) | None | 13 | pT3b | 6 | + | ++ | + | ++ |
| 17 | EBRT (70) | LHRH | 34 | pT3b | 10 | +++ | ++ | + | ++ |
cnd, could not be determined; EBRT, external beam radiotherapy; HDR, high dose rate; LDR, low dose rate; LHRH, luteinizing-hormone-releasing hormone agonist; AA, androgen receptor antagonist.